[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse SOX9

Summary
SymbolSOX9
NameSRY (sex determining region Y)-box 9
Aliases CMD1; campomelic dysplasia, autosomal sex-reversal; SRXX2; SRXY10; SRY (sex-determining region Y)-box 9 prot ......
Chromosomal Location17q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF00505 HMG (high mobility group) box
PF12444 Sox developmental protein N terminal
Function

Transcriptional regulator (PubMed:24038782). Binds to the COL2A1 promoter and activates COL2A1 expression, as part of a complex with ZNF219 (By similarity). Plays a role in chondrocyte differentiation (By similarity). Important for normal skeletal development (PubMed:24038782).

> Gene Ontology
 
Biological Process GO:0001101 response to acid chemical
GO:0001501 skeletal system development
GO:0001502 cartilage condensation
GO:0001503 ossification
GO:0001654 eye development
GO:0001655 urogenital system development
GO:0001656 metanephros development
GO:0001657 ureteric bud development
GO:0001658 branching involved in ureteric bud morphogenesis
GO:0001667 ameboidal-type cell migration
GO:0001708 cell fate specification
GO:0001754 eye photoreceptor cell differentiation
GO:0001763 morphogenesis of a branching structure
GO:0001822 kidney development
GO:0001823 mesonephros development
GO:0001837 epithelial to mesenchymal transition
GO:0001838 embryonic epithelial tube formation
GO:0001889 liver development
GO:0001894 tissue homeostasis
GO:0001942 hair follicle development
GO:0002053 positive regulation of mesenchymal cell proliferation
GO:0002062 chondrocyte differentiation
GO:0002063 chondrocyte development
GO:0002064 epithelial cell development
GO:0002683 negative regulation of immune system process
GO:0003007 heart morphogenesis
GO:0003170 heart valve development
GO:0003179 heart valve morphogenesis
GO:0003188 heart valve formation
GO:0003197 endocardial cushion development
GO:0003203 endocardial cushion morphogenesis
GO:0003338 metanephros morphogenesis
GO:0003401 axis elongation
GO:0003407 neural retina development
GO:0003413 chondrocyte differentiation involved in endochondral bone morphogenesis
GO:0003415 chondrocyte hypertrophy
GO:0006323 DNA packaging
GO:0006333 chromatin assembly or disassembly
GO:0006334 nucleosome assembly
GO:0006338 chromatin remodeling
GO:0007173 epidermal growth factor receptor signaling pathway
GO:0007219 Notch signaling pathway
GO:0007283 spermatogenesis
GO:0007423 sensory organ development
GO:0007507 heart development
GO:0007530 sex determination
GO:0007538 primary sex determination
GO:0007542 primary sex determination, germ-line
GO:0007548 sex differentiation
GO:0007586 digestion
GO:0008406 gonad development
GO:0008544 epidermis development
GO:0008584 male gonad development
GO:0009612 response to mechanical stimulus
GO:0009894 regulation of catabolic process
GO:0009896 positive regulation of catabolic process
GO:0010001 glial cell differentiation
GO:0010463 mesenchymal cell proliferation
GO:0010464 regulation of mesenchymal cell proliferation
GO:0010631 epithelial cell migration
GO:0010632 regulation of epithelial cell migration
GO:0010634 positive regulation of epithelial cell migration
GO:0010669 epithelial structure maintenance
GO:0010721 negative regulation of cell development
GO:0014031 mesenchymal cell development
GO:0014032 neural crest cell development
GO:0014033 neural crest cell differentiation
GO:0014065 phosphatidylinositol 3-kinase signaling
GO:0014066 regulation of phosphatidylinositol 3-kinase signaling
GO:0014068 positive regulation of phosphatidylinositol 3-kinase signaling
GO:0016049 cell growth
GO:0016055 Wnt signaling pathway
GO:0016331 morphogenesis of embryonic epithelium
GO:0018992 germ-line sex determination
GO:0019100 male germ-line sex determination
GO:0019827 stem cell population maintenance
GO:0019932 second-messenger-mediated signaling
GO:0019933 cAMP-mediated signaling
GO:0019935 cyclic-nucleotide-mediated signaling
GO:0021781 glial cell fate commitment
GO:0022404 molting cycle process
GO:0022405 hair cycle process
GO:0022600 digestive system process
GO:0022612 gland morphogenesis
GO:0030111 regulation of Wnt signaling pathway
GO:0030178 negative regulation of Wnt signaling pathway
GO:0030198 extracellular matrix organization
GO:0030238 male sex determination
GO:0030277 maintenance of gastrointestinal epithelium
GO:0030278 regulation of ossification
GO:0030279 negative regulation of ossification
GO:0030282 bone mineralization
GO:0030323 respiratory tube development
GO:0030324 lung development
GO:0030335 positive regulation of cell migration
GO:0030500 regulation of bone mineralization
GO:0030502 negative regulation of bone mineralization
GO:0030850 prostate gland development
GO:0030856 regulation of epithelial cell differentiation
GO:0030857 negative regulation of epithelial cell differentiation
GO:0030858 positive regulation of epithelial cell differentiation
GO:0030879 mammary gland development
GO:0030903 notochord development
GO:0030916 otic vesicle formation
GO:0031016 pancreas development
GO:0031018 endocrine pancreas development
GO:0031128 developmental induction
GO:0031214 biomineral tissue development
GO:0031497 chromatin assembly
GO:0032330 regulation of chondrocyte differentiation
GO:0032331 negative regulation of chondrocyte differentiation
GO:0032332 positive regulation of chondrocyte differentiation
GO:0032526 response to retinoic acid
GO:0032808 lacrimal gland development
GO:0034504 protein localization to nucleus
GO:0034728 nucleosome organization
GO:0035019 somatic stem cell population maintenance
GO:0035107 appendage morphogenesis
GO:0035108 limb morphogenesis
GO:0035148 tube formation
GO:0035239 tube morphogenesis
GO:0035265 organ growth
GO:0035270 endocrine system development
GO:0035272 exocrine system development
GO:0035622 intrahepatic bile duct development
GO:0038127 ERBB signaling pathway
GO:0040017 positive regulation of locomotion
GO:0042063 gliogenesis
GO:0042176 regulation of protein catabolic process
GO:0042303 molting cycle
GO:0042471 ear morphogenesis
GO:0042472 inner ear morphogenesis
GO:0042633 hair cycle
GO:0042692 muscle cell differentiation
GO:0043010 camera-type eye development
GO:0043062 extracellular structure organization
GO:0043491 protein kinase B signaling
GO:0043583 ear development
GO:0043588 skin development
GO:0044089 positive regulation of cellular component biogenesis
GO:0045137 development of primary sexual characteristics
GO:0045165 cell fate commitment
GO:0045445 myoblast differentiation
GO:0045661 regulation of myoblast differentiation
GO:0045662 negative regulation of myoblast differentiation
GO:0045665 negative regulation of neuron differentiation
GO:0045732 positive regulation of protein catabolic process
GO:0046530 photoreceptor cell differentiation
GO:0046532 regulation of photoreceptor cell differentiation
GO:0046533 negative regulation of photoreceptor cell differentiation
GO:0046546 development of primary male sexual characteristics
GO:0046661 male sex differentiation
GO:0048015 phosphatidylinositol-mediated signaling
GO:0048017 inositol lipid-mediated signaling
GO:0048232 male gamete generation
GO:0048562 embryonic organ morphogenesis
GO:0048568 embryonic organ development
GO:0048588 developmental cell growth
GO:0048592 eye morphogenesis
GO:0048593 camera-type eye morphogenesis
GO:0048608 reproductive structure development
GO:0048705 skeletal system morphogenesis
GO:0048708 astrocyte differentiation
GO:0048709 oligodendrocyte differentiation
GO:0048732 gland development
GO:0048736 appendage development
GO:0048745 smooth muscle tissue development
GO:0048754 branching morphogenesis of an epithelial tube
GO:0048762 mesenchymal cell differentiation
GO:0048839 inner ear development
GO:0048863 stem cell differentiation
GO:0048864 stem cell development
GO:0048871 multicellular organismal homeostasis
GO:0048872 homeostasis of number of cells
GO:0048873 homeostasis of number of cells within a tissue
GO:0050673 epithelial cell proliferation
GO:0050678 regulation of epithelial cell proliferation
GO:0050679 positive regulation of epithelial cell proliferation
GO:0050680 negative regulation of epithelial cell proliferation
GO:0050768 negative regulation of neurogenesis
GO:0051145 smooth muscle cell differentiation
GO:0051147 regulation of muscle cell differentiation
GO:0051148 negative regulation of muscle cell differentiation
GO:0051216 cartilage development
GO:0051272 positive regulation of cellular component movement
GO:0051961 negative regulation of nervous system development
GO:0060008 Sertoli cell differentiation
GO:0060009 Sertoli cell development
GO:0060018 astrocyte fate commitment
GO:0060041 retina development in camera-type eye
GO:0060042 retina morphogenesis in camera-type eye
GO:0060070 canonical Wnt signaling pathway
GO:0060173 limb development
GO:0060174 limb bud formation
GO:0060219 camera-type eye photoreceptor cell differentiation
GO:0060221 retinal rod cell differentiation
GO:0060249 anatomical structure homeostasis
GO:0060348 bone development
GO:0060349 bone morphogenesis
GO:0060350 endochondral bone morphogenesis
GO:0060351 cartilage development involved in endochondral bone morphogenesis
GO:0060425 lung morphogenesis
GO:0060428 lung epithelium development
GO:0060433 bronchus development
GO:0060438 trachea development
GO:0060441 epithelial tube branching involved in lung morphogenesis
GO:0060479 lung cell differentiation
GO:0060485 mesenchyme development
GO:0060487 lung epithelial cell differentiation
GO:0060502 epithelial cell proliferation involved in lung morphogenesis
GO:0060512 prostate gland morphogenesis
GO:0060516 primary prostatic bud elongation
GO:0060517 epithelial cell proliferation involved in prostatic bud elongation
GO:0060532 bronchus cartilage development
GO:0060534 trachea cartilage development
GO:0060537 muscle tissue development
GO:0060541 respiratory system development
GO:0060560 developmental growth involved in morphogenesis
GO:0060562 epithelial tube morphogenesis
GO:0060602 branch elongation of an epithelium
GO:0060675 ureteric bud morphogenesis
GO:0060688 regulation of morphogenesis of a branching structure
GO:0060729 intestinal epithelial structure maintenance
GO:0060736 prostate gland growth
GO:0060737 prostate gland morphogenetic growth
GO:0060740 prostate gland epithelium morphogenesis
GO:0060767 epithelial cell proliferation involved in prostate gland development
GO:0060784 regulation of cell proliferation involved in tissue homeostasis
GO:0060828 regulation of canonical Wnt signaling pathway
GO:0060993 kidney morphogenesis
GO:0061008 hepaticobiliary system development
GO:0061009 common bile duct development
GO:0061035 regulation of cartilage development
GO:0061036 positive regulation of cartilage development
GO:0061037 negative regulation of cartilage development
GO:0061046 regulation of branching involved in lung morphogenesis
GO:0061138 morphogenesis of a branching epithelium
GO:0061145 lung smooth muscle development
GO:0061213 positive regulation of mesonephros development
GO:0061217 regulation of mesonephros development
GO:0061323 cell proliferation involved in heart morphogenesis
GO:0061326 renal tubule development
GO:0061333 renal tubule morphogenesis
GO:0061448 connective tissue development
GO:0061458 reproductive system development
GO:0061614 pri-miRNA transcription from RNA polymerase II promoter
GO:0065004 protein-DNA complex assembly
GO:0070167 regulation of biomineral tissue development
GO:0070168 negative regulation of biomineral tissue development
GO:0070371 ERK1 and ERK2 cascade
GO:0070384 Harderian gland development
GO:0070555 response to interleukin-1
GO:0070849 response to epidermal growth factor
GO:0071103 DNA conformation change
GO:0071214 cellular response to abiotic stimulus
GO:0071229 cellular response to acid chemical
GO:0071260 cellular response to mechanical stimulus
GO:0071300 cellular response to retinoic acid
GO:0071347 cellular response to interleukin-1
GO:0071364 cellular response to epidermal growth factor stimulus
GO:0071396 cellular response to lipid
GO:0071417 cellular response to organonitrogen compound
GO:0071496 cellular response to external stimulus
GO:0071503 response to heparin
GO:0071504 cellular response to heparin
GO:0071559 response to transforming growth factor beta
GO:0071560 cellular response to transforming growth factor beta stimulus
GO:0071599 otic vesicle development
GO:0071600 otic vesicle morphogenesis
GO:0071824 protein-DNA complex subunit organization
GO:0072001 renal system development
GO:0072006 nephron development
GO:0072009 nephron epithelium development
GO:0072028 nephron morphogenesis
GO:0072033 renal vesicle formation
GO:0072034 renal vesicle induction
GO:0072073 kidney epithelium development
GO:0072077 renal vesicle morphogenesis
GO:0072078 nephron tubule morphogenesis
GO:0072079 nephron tubule formation
GO:0072080 nephron tubule development
GO:0072087 renal vesicle development
GO:0072088 nephron epithelium morphogenesis
GO:0072132 mesenchyme morphogenesis
GO:0072163 mesonephric epithelium development
GO:0072164 mesonephric tubule development
GO:0072170 metanephric tubule development
GO:0072171 mesonephric tubule morphogenesis
GO:0072173 metanephric tubule morphogenesis
GO:0072174 metanephric tubule formation
GO:0072175 epithelial tube formation
GO:0072189 ureter development
GO:0072190 ureter urothelium development
GO:0072191 ureter smooth muscle development
GO:0072193 ureter smooth muscle cell differentiation
GO:0072197 ureter morphogenesis
GO:0072207 metanephric epithelium development
GO:0072210 metanephric nephron development
GO:0072234 metanephric nephron tubule development
GO:0072243 metanephric nephron epithelium development
GO:0072273 metanephric nephron morphogenesis
GO:0072282 metanephric nephron tubule morphogenesis
GO:0072289 metanephric nephron tubule formation
GO:0072497 mesenchymal stem cell differentiation
GO:0085029 extracellular matrix assembly
GO:0090090 negative regulation of canonical Wnt signaling pathway
GO:0090102 cochlea development
GO:0090103 cochlea morphogenesis
GO:0090130 tissue migration
GO:0090132 epithelium migration
GO:0090183 regulation of kidney development
GO:0090184 positive regulation of kidney development
GO:0090189 regulation of branching involved in ureteric bud morphogenesis
GO:0090190 positive regulation of branching involved in ureteric bud morphogenesis
GO:0090596 sensory organ morphogenesis
GO:0097152 mesenchymal cell apoptotic process
GO:0098727 maintenance of cell number
GO:0098743 cell aggregation
GO:0098773 skin epidermis development
GO:0198738 cell-cell signaling by wnt
GO:1901201 regulation of extracellular matrix assembly
GO:1901203 positive regulation of extracellular matrix assembly
GO:1902893 regulation of pri-miRNA transcription from RNA polymerase II promoter
GO:1902894 negative regulation of pri-miRNA transcription from RNA polymerase II promoter
GO:1903053 regulation of extracellular matrix organization
GO:1903055 positive regulation of extracellular matrix organization
GO:1905330 regulation of morphogenesis of an epithelium
GO:1905332 positive regulation of morphogenesis of an epithelium
GO:2000018 regulation of male gonad development
GO:2000020 positive regulation of male gonad development
GO:2000027 regulation of organ morphogenesis
GO:2000136 regulation of cell proliferation involved in heart morphogenesis
GO:2000138 positive regulation of cell proliferation involved in heart morphogenesis
GO:2000147 positive regulation of cell motility
GO:2000241 regulation of reproductive process
GO:2000243 positive regulation of reproductive process
GO:2000736 regulation of stem cell differentiation
GO:2000738 positive regulation of stem cell differentiation
GO:2000739 regulation of mesenchymal stem cell differentiation
GO:2000741 positive regulation of mesenchymal stem cell differentiation
GO:2000794 regulation of epithelial cell proliferation involved in lung morphogenesis
GO:2000826 regulation of heart morphogenesis
GO:2001053 regulation of mesenchymal cell apoptotic process
GO:2001054 negative regulation of mesenchymal cell apoptotic process
Molecular Function GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001046 core promoter sequence-specific DNA binding
GO:0001047 core promoter binding
GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001158 enhancer sequence-specific DNA binding
GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding
GO:0003682 chromatin binding
GO:0003705 transcription factor activity, RNA polymerase II distal enhancer sequence-specific binding
GO:0008013 beta-catenin binding
GO:0008134 transcription factor binding
GO:0034236 protein kinase A catalytic subunit binding
GO:0035326 enhancer binding
GO:0036002 pre-mRNA binding
GO:0043425 bHLH transcription factor binding
GO:0046982 protein heterodimerization activity
GO:0051018 protein kinase A binding
GO:0097157 pre-mRNA intronic binding
Cellular Component GO:0005667 transcription factor complex
GO:0044798 nuclear transcription factor complex
> KEGG and Reactome Pathway
 
KEGG hsa04024 cAMP signaling pathway
Reactome R-HSA-3769402: Deactivation of the beta-catenin transactivating complex
R-HSA-162582: Signal Transduction
R-HSA-195721: Signaling by Wnt
R-HSA-201681: TCF dependent signaling in response to WNT
Summary
SymbolSOX9
NameSRY (sex determining region Y)-box 9
Aliases CMD1; campomelic dysplasia, autosomal sex-reversal; SRXX2; SRXY10; SRY (sex-determining region Y)-box 9 prot ......
Chromosomal Location17q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SOX9 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between SOX9 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
27015306Lung Carcinoma; Breast CarcinomaInhibit immunityLCC cells show stem-cell-like characteristics and express SOX2 and SOX9 transcription factors, which are essential for their survival in host organs under immune surveillance and for metastatic outgrowth under permissive conditions.
Summary
SymbolSOX9
NameSRY (sex determining region Y)-box 9
Aliases CMD1; campomelic dysplasia, autosomal sex-reversal; SRXX2; SRXY10; SRY (sex-determining region Y)-box 9 prot ......
Chromosomal Location17q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SOX9 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSOX9
NameSRY (sex determining region Y)-box 9
Aliases CMD1; campomelic dysplasia, autosomal sex-reversal; SRXX2; SRXY10; SRY (sex-determining region Y)-box 9 prot ......
Chromosomal Location17q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SOX9 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1910.79
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.4240.788
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0210.986
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.8320.206
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.8650.605
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.8040.74
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.6520.335
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.9690.465
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.3210.823
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-1.1940.357
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-1.1950.496
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3520.227
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SOX9 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.41.460.177
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.41.75.70.231
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.63.7-1.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.57.7-3.21
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolSOX9
NameSRY (sex determining region Y)-box 9
Aliases CMD1; campomelic dysplasia, autosomal sex-reversal; SRXX2; SRXY10; SRY (sex-determining region Y)-box 9 prot ......
Chromosomal Location17q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SOX9. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSOX9
NameSRY (sex determining region Y)-box 9
Aliases CMD1; campomelic dysplasia, autosomal sex-reversal; SRXX2; SRXY10; SRY (sex-determining region Y)-box 9 prot ......
Chromosomal Location17q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SOX9. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SOX9.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSOX9
NameSRY (sex determining region Y)-box 9
Aliases CMD1; campomelic dysplasia, autosomal sex-reversal; SRXX2; SRXY10; SRY (sex-determining region Y)-box 9 prot ......
Chromosomal Location17q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SOX9. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSOX9
NameSRY (sex determining region Y)-box 9
Aliases CMD1; campomelic dysplasia, autosomal sex-reversal; SRXX2; SRXY10; SRY (sex-determining region Y)-box 9 prot ......
Chromosomal Location17q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SOX9 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSOX9
NameSRY (sex determining region Y)-box 9
Aliases CMD1; campomelic dysplasia, autosomal sex-reversal; SRXX2; SRXY10; SRY (sex-determining region Y)-box 9 prot ......
Chromosomal Location17q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SOX9 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSOX9
NameSRY (sex determining region Y)-box 9
Aliases CMD1; campomelic dysplasia, autosomal sex-reversal; SRXX2; SRXY10; SRY (sex-determining region Y)-box 9 prot ......
Chromosomal Location17q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SOX9 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.